Recent Updates
Recently added Catalysts

COMPASS Pathways Plc - American Depository Shares

CMPSFDA catalysts, PDUFA dates & pipeline intelligence
$7.98
▼ -0.29 · -3.51%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full CMPS financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $4.8852W HIGH $15.87
Volume
2.70 M
Value Traded
21.59 M
Short % Float
12.34%
Days to Cover
7.7
-14.19%Week
-28.17%1 Month
-43.04%3 Month
-26.59%6 Month
-67.01%5 Year
-49.53%All Time

Cash Data

Unlock CMPS cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
1.13 B
EPS (TTM)
-1.88
P/E Ratio
-
Ent. Value
739.28 M
Total Shares
141.71 M
Float Shares
139.40 M
Insiders
1.61%
Institutions
67.59%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
NDA Submission
COMP360
treatment-resistant depression (TRD)
Breakthrough
NDASmall MoleculesPsychiatry
Unlock every CMPS catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

CMPS Catalyst Timeline

Dated clinical, regulatory and corporate events for COMPASS Pathways Plc - American Depository Shares

Catalyst Timeline

Dated clinical, regulatory & corporate events for COMPASS Pathways Plc - American Depository Shares

106Total events
13Upcoming
24Tier-1 (high impact)
2020 to 2028Coverage

Upcoming catalysts 2

T1NDA Submission
Subscribe to view catalyst details
COMP360Filed
T2R&D Day
Subscribe to view catalyst details

Event history 50

●NDA SubmissionCOMP360FiledRegulatory Filing
Compass completes NDA submission to U.S. FDA for COMP360 psilocybin in TRD
treatment-resistant depressionsource ↗
●Quarterly UpdateCorporate
Compass Pathways reports third quarter 2026 financial results
▲Long Term DataCOMP360FiledClinical Data
52-week open label data from COMP005 showing durability to one year
treatment-resistant depression (TRD)source ↗
●Equity OfferingCorporate
Compass grants inducement equity awards to nine new employees
●Equity OfferingCorporate
Equity awards granted to ten newly hired non-executive employees
●Management ChangeCorporate
Kelley Boucher appointed Chief People Officer, effective today
●Equity OfferingCorporate
Equity awards granted to senior leader under 2026 Inducement Plan
●Timing GuidancePresentation
Compass Pathways launches 'Change the Tune in TRD' U.S. HCP disease education initiative
treatment-resistant depressionsource ↗
▲Grant / FundingCOMP360FiledCorporate
Strata Mental Health Solutions awarded one of five U.S. HCP training grants from Compass Pathways for COMP360 provider training
▲Grant / FundingCOMP360FiledCorporate
Fluence selected by Compass Pathways as recipient of U.S. healthcare provider training grant program
treatment-resistant depressionsource ↗
Unlock the full CMPS catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How CMPS actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
2026-11-05COMP360 psilocybin Phase 3 data presentation Phase 3
Unlock 3 more CMPS historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

Pipeline Score
Pipeline Value
Valuation Signal
1
Drugs Scored
rNPV / MCap
Top Drug
Top 31%
Micro Cap
(rank 225 of 725)
Percentile Rank
Showing 5 of 6 assets
DrugIndicationPhasePTRSrNPVStatusEnrollVelocityDesignEst. CompletionML SignalLast Change
COMP360 Small MoleculesNCT05711940Treatment Resistant DepressionPhase 3 ACTIVE NOT_RECRUITING 1,082Dec 1, 2026
COMP360 psilocybin Small MoleculesNCT07570654PTSD - Post Traumatic Stress DisorderPhase 2/3 RECRUITING 300Sep 1, 2029
COMP360 Small MoleculesNCT05733546Major Depressive DisorderPhase 2 ACTIVE NOT_RECRUITING 122Sep 1, 2025
COMP360 Small MoleculesCompletedNCT05312151Post Traumatic Stress DisorderPhase 2 COMPLETED 22Feb 12, 2024
COMP360 Small MoleculesCompletedNCT05481736Anorexia NervosaPhase 2 COMPLETED 48Nov 18, 2024
Unlock the CMPS pipeline intelligence model
PTRS, rNPV, enrollment velocity, trial design quality and ML risk signals for every asset above.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every CMPS program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
COMP360
Breakthrough
treatment-resistant depressionPhase 32026-09-0952-week resultsRead MoreCompass Pathways’ New 52-Week Topline Open-Label Data from Phase 3 COMP005 Trial Demonstrates Additional Benefit from Another COMP360 Dose in Part C Extending Durability Out to 1 YearRead More
Scroll for more · summaries link to the source press release
Unlock every CMPS trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock CMPS insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
Karydas DaphneDirectorGrant/Award 21,110 21,110 held$0.00 05/27/2026
Unlock the full CMPS insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Fund % of Portfolio Current MV Shares Owned Activity
Deep Track Capital, LP 2.5 % 151.29 M 12.16 M
Unlock every fund holding CMPS
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in CMPS
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see CMPS ownership
Insider and institutional ownership, quarter by quarter.

CMPS Short Interest

Shares sold short, counted twice a month.

12.34%
Short % of Float
of tradable shares sold short
17.2M
Shares Sold Short
-2.7% vs prior count
7.7 High
Days to Cover
trading days of normal volume to buy every short share back
2.2M
Avg Daily Volume
the average used for days to cover
Unlock CMPS short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Option Volume

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
2026-11-20
Unlock CMPS option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live CMPS option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock CMPS options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How CMPS ranks across every disease it competes in

Competitive Position is a premium feature
See how CMPS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

CMPS News

CMPS
Nov 11, 2026
CMPSConferences/Events

Compass Pathways to Participate in Jefferies Global Healthcare Conference on November 18th and 19th

Compass Pathways will attend the Jefferies Global Healthcare Conference on November 18 and 19, 2026. Management will engage in a fireside chat and a panel discussion, focusing on their innovative mental health treatments. The company is advancing its investigational psilocybin treatment, COMP360, for treatment-resistant depression and PTSD.

Read more →
CMPS
Nov 9, 2026
CMPSFDA Updates
▲ +6.6%on this newsshared move

Compass Pathways Completes COMP360 Psilocybin New Drug Application to U.S. FDA for Treatment-Resistant Depression

Compass Pathways has submitted a New Drug Application (NDA) to the FDA for COMP360 psilocybin, targeting treatment-resistant depression (TRD). The submission is backed by data from two Phase 3 trials and a Phase 2b study involving over 1,000 participants. The company aims for a commercial launch in H1 2027, pending FDA approval.

Read more →
CMPS
Nov 5, 2026
CMPSGeneral
▲ +10.2%on this newsshared move

Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Compass Pathways announced the granting of equity awards to nine new employees under its 2026 Inducement Plan. The awards include options for 59,275 shares and restricted share units, with an exercise price of $8.41. This move is part of the company's strategy to attract talent while advancing its mental health treatment initiatives.

Read more →
CMPS
Nov 4, 2026
CMPSConferences/Events

Compass Pathways to Participate in Stifel 2026 Healthcare Conference on November 11th

Compass Pathways will attend the Stifel 2026 Healthcare Conference on November 11, 2026. Management will participate in a fireside chat at 8:40am ET. The company is focused on developing COMP360, a synthetic psilocybin treatment for treatment-resistant depression and PTSD, which has received FDA Breakthrough Therapy designation.

Read more →
CMPS
Nov 3, 2026
CMPSFDA Updates

Compass Pathways Announces Third Quarter 2026 Financial Results and Business Highlights

Compass Pathways reported its Q3 2026 financial results, highlighting the imminent NDA submission for COMP360, expected within two weeks. The company anticipates a launch in H1 2027, pending FDA approval. Positive Phase 3 trial data suggests COMP360 could redefine treatment for treatment-resistant depression (TRD), addressing a significant market need.

Read more →
CMPS
Nov 2, 2026
CMPSGeneral
▼ -27.3%on this newsshared move

New Joint Survey from Compass Pathways and the Depression and Bipolar Support Alliance Reveals the Lived Burden of Treatment-Resistant Depression on Patients and Caregivers

Compass Pathways and DBSA released a survey revealing the significant burden of treatment-resistant depression (TRD) on patients and caregivers. The survey indicates that 95% of patients feel they are merely surviving, with many reporting emotional exhaustion from ineffective treatments. Caregivers also face substantial emotional and financial strains, highlighting the urgent need for improved treatment options.

Read more →
CMPS
Oct 28, 2026
CMPSConferences/Events

Compass Pathways to Highlight Scientific Research and TRD Disease State Education Efforts at the 2026 Neuroscience Education Institute Fall Congress

Compass Pathways will participate in the 2026 Neuroscience Education Institute Fall Congress, focusing on treatment-resistant depression (TRD). The company will present its educational campaign, 'Change the Tune in TRD,' and encore presentations from its COMP360 psilocybin clinical program. This event aims to enhance understanding among U.S. healthcare professionals.

Read more →
CMPS
Oct 27, 2026
CMPSGeneral
▲ +6.9%on this newsshared move

Compass Pathways to Announce Third Quarter 2026 Financial Results on November 3, 2026

Compass Pathways plc will announce its third quarter 2026 financial results on November 3, 2026. The company will also provide updates on recent developments during a conference call at 8:00 am ET. Compass is focused on developing COMP360 psilocybin for treatment-resistant depression and PTSD, with significant designations from regulatory bodies.

Read more →
CMPS
Oct 14, 2026
CMPSGeneral

Compass Pathways Joins Forces with Leading Mental Health Organizations to Mark First-Ever U.S. Treatment-Resistant Depression (TRD) Awareness Day

Compass Pathways has announced the first-ever Treatment-Resistant Depression (TRD) Awareness Day in the U.S., aimed at raising awareness about the condition and its impact on patients and caregivers. The initiative is supported by major mental health organizations and seeks to foster understanding and support for those affected by TRD. A report detailing the burden of TRD will be released in the future.

Read more →
CMPS
Oct 5, 2026
CMPSGeneral

Compass Pathways Celebrates Opening of New U.S. Office in Jersey City, New Jersey

Compass Pathways has inaugurated its new U.S. office in Jersey City, New Jersey, which will serve as a hub for its employees in the tri-state area. This 6,327-square-foot facility aims to support the company's efforts in advancing its investigational treatment, COMP360, for treatment-resistant depression. The CEO highlighted the importance of this milestone in the company's growth and commitment to improving mental health care.

Read more →
CMPS
Sep 30, 2026
CMPSGeneral

Compass Pathways Appoints Kelley Boucher as Chief People Officer

Compass Pathways has appointed Kelley Boucher as Chief People Officer, effective immediately. This strategic move aims to strengthen the executive team as the company focuses on scaling its operations. The appointment aligns with Compass's mission to introduce innovative psychedelic treatments in psychiatry.

Read more →
CMPS
Sep 16, 2026
CMPSConferences/Events

Compass Pathways to Participate in TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit on September 23, 2026

Compass Pathways plc will participate in the TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit on September 23, 2026. The company will host a fireside chat at 1:00 pm ET, which will be available via a live audio webcast. Compass is focused on developing innovative treatments for mental health, including its investigational psilocybin treatment, COMP360.

Read more →
CMPS
Sep 15, 2026
CMPSGeneral
▼ -5%on this newsshared move

Compass Pathways Launches ‘Change the Tune in TRD’ in the U.S. to Advance HCP Understanding of Treatment-Resistant Depression at Psych Congress 2026

Compass Pathways has launched the 'Change the Tune in TRD' initiative aimed at enhancing healthcare provider understanding of treatment-resistant depression (TRD). This campaign will delve into the neurobiology of TRD and assist in navigating care pathways for both patients and providers. The initiative was announced during the Psych Congress 2026.

Read more →
CMPS
Sep 11, 2026
CMPSGeneral

Strata Mental Health Solutions Awarded U.S. Healthcare Provider Training Grant from Compass Pathways to Develop Provider Training for COMP360

Strata Mental Health Solutions has received a grant from Compass Pathways to develop training programs for healthcare providers regarding COMP360, an investigational psilocybin treatment. This initiative aims to prepare clinical networks for the potential delivery of psychedelic treatments. The collaboration highlights Strata's expertise in the field.

Read more →
CMPS
Sep 10, 2026
CMPSGeneral
▼ -6.3%on this newsshared move

Fluence Selected by Compass Pathways to Develop Post-Approval COMP360 Provider Training

Fluence has been selected by Compass Pathways to develop a certificate program for healthcare providers in anticipation of the FDA's approval of COMP360, a psilocybin treatment for depression. The program will consist of three modules aimed at equipping clinicians with the necessary skills and knowledge to support patients. This collaboration emphasizes Fluence's dedication to translating research into clinical practice.

Read more →
CMPS
Sep 10, 2026
CMPSGeneral
▼ -6.3%on this newsshared move

Compass Pathways Announces U.S. Grant Program Recipients for the Development of Post-Approval COMP360 Provider Training

Compass Pathways has announced the recipients of its U.S. grant program aimed at developing training for healthcare providers to deliver COMP360, a psilocybin treatment for treatment-resistant depression. The program awarded grants to five organizations, expanding from the initial plan of three due to high-quality applicants. This initiative is part of Compass's commitment to ensuring effective treatment delivery upon COMP360's potential approval.

Read more →
CMPS
Sep 10, 2026
CMPSConferences/Events
▼ -6.3%on this newsshared move

Compass Pathways to Participate in Investor Conferences the Week of September 14th

Compass Pathways plc will participate in investor conferences during the week of September 14th. The company aims to engage with investors at the H.C. Wainwright Annual Global Investment Conference and the Morgan Stanley 24th Annual Global Healthcare Conference. These events will provide a platform for discussing their innovative approaches in mental health care.

Read more →
CMPS
Sep 9, 2026
CMPSPhases
▲ +8%on this newsshared move

Compass Pathways’ New 52-Week Topline Open-Label Data from Phase 3 COMP005 Trial Demonstrates Additional Benefit from Another COMP360 Dose in Part C Extending Durability Out to 1 Year

Compass Pathways has released topline results from the Phase 3 COMP005 trial of COMP360, a psilocybin formulation for treatment-resistant depression. The open-label Part C data indicates an additional benefit from another dose, extending the treatment's durability to one year. This supports the drug's differentiated profile and potential for long-term effectiveness.

Read more →
CMPS
Sep 8, 2026
CMPSConferences/Events
▲ +5.8%on this newsshared move

Compass Pathways to Debut U.S. HCP Education Campaign and Present New HEOR Data at Psych Congress 2026

Compass Pathways is set to launch its 'Change the Tune in TRD' education campaign at Psych Congress 2026, focusing on treatment-resistant depression (TRD). The company will also present new health economics and outcomes research data, alongside findings from its COMP360 psilocybin clinical trials. This initiative aims to enhance healthcare provider education on TRD.

Read more →

About COMPASS Pathways Plc - American Depository Shares

Chesire, X0 156 employees compasspathways.com
Headquarters3RD FLOOR, 1 ASHLEY ROAD, CHESIRE, X0, WA14 2DT
BIOPHARMAWATCH ELITE
Trade the next CMPS catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime